SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Swiss expo to explore European cannabis legalisation

    By
    Home / Swiss expo to explore European cannabis legalisation

    This year’s CB Expo for CBD and medical cannabis is giving companies products, brands and services the opportunity to network and discover Switzerland’s potential for producing and importing cannabis products.

    Since the beginning of August, medical cannabis can be prescribed by doctors in Switzerland without a licence from the health ministry (FOPH). The export of cannabis is now permitted and the first products from the pilot trials in Basel will be  going over the counter this autumn. 

    The Swiss cannabis industry is developing, and the second edition of the Cannabis Business Expo (CB Expo) on 10 and 11 September in Zurich, will explore trends in the industry and the discussion about legalisation models in Europe.

    Discover more cannabis events on the Cannabis Wealth event page

    Main topics at the event will include the pilot projects in Switzerland, as well as the market development for recreational use of cannabis in the country.

    Swiss company, Vigia, the company behind the compliance software Cannavigia, is taking part in the CB Expo and will be a Gold Sponsor at this year’s edition.

    CEO of Vigia, Luc Richner, commented: “The CB Expo is the perfect opportunity to further network with the European, and especially the Swiss industry, to gain potential customers and to exchange information about the upcoming legalisation in Europe.

    “Especially in our still young but rapidly growing industry, it is essential to work together. 

    “CB Expo is an excellent trade fair  and gives our industry a good platform to advance the discourse. As a Gold Sponsor, we want to support exactly that and draw attention to the emerging cannabis industry in  Switzerland”.

    Vigia is also actively participating in this discourse and is involved in the pilot projects. 

    With its track and trace software solution  Cannavigia, the company is an official partner of the FOPH (Federal Office for Public Health) for the pilot trials, allowing cannabis in the trial to be digitised and tracked from cultivation through to processing and distribution. This generates transparency, complete traceability of the cannabis sold and trust. 

    [activecampaign form=31]

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.